Top news of the week: 21.02.2023.
AI is dreaming up drugs that no one has ever seen. Now we’ve got to see if they work.
AI automation throughout the drug development pipeline is opening up the possibility of faster, cheaper pharmaceuticals.
With Aera, CRISPR pioneer Feng Zhang goes after gene therapy’s delivery problem
The company’s platform technology is built on research from Zhang’s lab at the Broad Institute, which focuses on a proteins that could be used to package and deliver nucleic acids.
We Will Never Fully Understand How AI Works — But That Shouldn’t Stop You From Using It
To unlock the true potential of artificial intelligence, investors need to accept the black box.
Investors bet big on Feng Zhang’s new startup, out to solve one of gene editing’s most vexing problems
Aera Therapeutics is launching with $193 million to develop a new nanoparticle technology to deliver genetic medicines to hard-to-reach parts of the body.
Apellis wins FDA approval of first drug for type of vision loss
Apellis’ Syfovre is the first marketed treatment for geographic atrophy, a common and irreversible eye condition. But questions linger about its benefit and safety.
InnovationRx: Artificial Intelligence In Biopharma; Plus, Lingering Covid Symptoms
InnovationRx is your weekly digest of healthcare news. Sign up!
CERES Lab Offers Industry Researchers Opportunity to Accelerate Development of Innovative Health Treatments
Kenneth Dwyer, a sales and marketing professional with extensive experience in the life sciences industry, has joined WPI as laboratory manager of the university’s Cell Engineering Research ...
Gilead’s Shaw to step down from role running cell therapy unit
Shaw, who joined Gilead in 2019 from Eli Lilly, helped build Kite into a leading producer of cell therapies, convincing Wall Street skeptics in the process.